Prevention of Toxin-Induced Intestinal Ion and Fluid Secretion by a Small-Molecule CFTR Inhibitor

Gastroenterology

Volumn 126, Issue 2, 2004, Pages 511-519

  Thiagarajah, Jay R ^a   Broadbent, Talmage ^a   Hsieh, Emily ^a   Verkman, Alan S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3 TRIFLUOROMETHYL)PHENYL] 5 [(3 CARBOXYPHENYL)METHYLENE] 2 THIOXO 4 THIAZOLIDINONE; CHOLERA TOXIN; CYCLIC AMP; CYCLIC GMP; ESCHERICHIA COLI ENTEROTOXIN; PROTEIN INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLORIDE TRANSPORT; CHOLERA; COLON MUCOSA; CONTROLLED STUDY; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; INTESTINE FLUID; INTESTINE SECRETION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SHORT CIRCUIT CURRENT; TISSUE DISTRIBUTION;

EID: 0842300379     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2003.11.005     Document Type: Article

References (34)

1. Claeson M, Merson MH. Global progress in the control of diarrheal diseases. Pediatr Infect Dis 1990;9:345-355.
2. Bern C, Martines J, de Zoysa I, Glass RI. The magnitude of the global problem of diarrhoeal disease: a ten-year update. Bull WHO 1992;70:705-714.
3. Glass RI, Lew JF, Gangarosa RE, LeBaron CW, Ho MS. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr 1991;118:S27-S33.
4. Lew JF, Glass RI, Gangarosa RE, Cohen IP, Bern C, Moe CL. Diarrheal deaths in the United States, 1979 through 1987. A special problem for the elderly. JAMA 1991;265:3280-3284.
5. Desjeux JF, Briend A, Butzner JD. Oral rehydration solution in the year 2000: pathophysiology, efficacy and effectiveness. Baillieres Clin Gastroenterol 1997;11:509-527.
6. Oldfield EC III, Wallace MR. The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001;30: 817-836.
7. Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev 1996; 60:167-215.
8. Gyles CL. Escherichia coli cytotoxins and enterotoxins. Can J Microbiol 1992;38:734-746.
9. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000;62:535-572.
10. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994;266:107-109.
11. - channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 1994;13:1065-1072.
12. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002;82:245-289.
13. O'Donnell EK, Sedlacek RL, Singh AK, Schultz BD. Inhibition of enterotoxin-induced porcine colonic secretion by diarylsulfonylureas in vitro. Am J Physiol 2000;279:G1104-G1112.
14. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera-toxin induced intestinal fluid secretion. J Clin Invest 2002;110:1651-1658.
15. Thiagarajah J, Broadbent T, Nagatani R, Sonawane ND, Song Y, Verkman AS. Antidiarrheal properties and pharmacology of a small molecule CFTR inhibitor. Ped Pulmonol 2003;(Suppl 25): 213.
16. Gorbach SL, Banwell JG, Chatterjee BD, Jacobs B, Sack RB. Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal microflora. J Clin Invest 1971;50:881-889.
17. Oi H, Matsuura D, Miyake M, Ueno M, Takai I, Yamamoto T, Kubo M, Moss J, Noda M. Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci U S A 2002; 99:3042-3046.
18. Stenberg P, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 2001;44:1927-1937.
19. Prasad YV, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N, Takada K. Enhanced intestinal absorption of vancomycin with Labrasol and D-α-tocopheryl PEG 1000 succinate in rats. Int J Pharm 2003;250:181-190.
20. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996;85:1142-1169.
21. Gyomorey K, Garami E, Galley K, Rommens JM, Bear CE. Non-CFTR chloride channels likely contribute to secretion in the murine small intestine. Pflugers Arch 2001;443:S103-S106.
22. Cohen MB, Thompson MR, Giannella RA. Differences in jejunal and ileal response to E. coli enterotoxin: possible mechanisms. Am J Physiol 1989;257:G118-G123.
23. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran N, Galietta LJV, Verkman AS. High-affinity activators of CFTR chloride conductance identified by high-throughput screening. J Biol Chem 2002;277:37235-37241.
24. Barrett KE. Positive and negative regulation of chloride secretion in T84 cells. Am J Physiol 1993;265:C859-C868.
25. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002;82:245-289.
26. Kimberg DV, Field M, Johnson J, Henderson A, Gershon E. Stimulation of intestinal mucosal adenyl cyclase by cholera enterotoxin and prostaglandins. J Clin Invest 1971;50:1218-1230.
27. Cassuto J, Jodal M, Tuttle R, Lundgren O. 5-Hydroxytryptamine and cholera secretion. Physiological and pharmacological studies in cats and rats. Scand J Gastroenterol 1982;17:695-703.
28. Bearcroft CP, Perrett D, Farthing MJ. 5-Hydroxytryptamine release into human jejunum by cholera toxin. Gut 1996;39:528-531.
29. Beubler E, Kollar G, Saria A, Bukhave K, Rask-Madsen J. Involvement of 5-hydroxytryptamine, prostaglandin E2, and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology 1989;96: 368-376.
30. Mezoff AG, Giannella RA, Eade MN, Cohen MB. Escherichia coli enterotoxin (STa) binds to receptors, stimulates guanyl cyclase, and impairs absorption in rat colon. Gastroenterology 1992;102: 816-822.
31. Lucas ML. A reconsideration of the evidence for Escherichia coli STa (heat stable) enterotoxin-driven fluid secretion: a new view of STa action and a new paradigm for fluid absorption. J Appl Microbiol 2001;90:7-26.
32. Pratha VS, Hogan DL, Martensson BA, Bernard J, Zhou R, Isenberg JI. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology 2000;118:1051-1060.
33. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett 2004;(in press).
34. 2+ mediated I-influx into intestinal crypts of CF mice. Am J Physiol 1999;277:G431-G444.